Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 77

Similar articles for PubMed (Select 21435899)

1.

Time for a new era in the evaluation of targeted therapies for patients with chronic myeloid leukemia: inclusion of quality of life and other patient-reported outcomes.

Efficace F, Cocks K, Breccia M, Sprangers M, Meyers CA, Vignetti M, Baccarani M, Mandelli F; GIMEMA and EORTC Quality of Life Group.

Crit Rev Oncol Hematol. 2012 Feb;81(2):123-35. doi: 10.1016/j.critrevonc.2011.02.007. Epub 2011 Mar 24. Review.

PMID:
21435899
2.
3.

Treatment options for chronic myeloid leukemia: imatinib versus interferon versus allogeneic transplant.

Angstreich GR, Smith BD, Jones RJ.

Curr Opin Oncol. 2004 Mar;16(2):95-9. Review.

PMID:
15075898
4.
5.

Health-related quality of life assessment and reported outcomes in leukaemia randomised controlled trials - a systematic review to evaluate the added value in supporting clinical decision making.

Efficace F, Kemmler G, Vignetti M, Mandelli F, Molica S, Holzner B.

Eur J Cancer. 2008 Jul;44(11):1497-506. doi: 10.1016/j.ejca.2008.03.017. Epub 2008 Jun 12. Review.

PMID:
18555682
6.

Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis.

Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH.

Ann Intern Med. 1997 Dec 15;127(12):1080-8.

PMID:
9412310
7.

An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology.

Silver RT, Woolf SH, Hehlmann R, Appelbaum FR, Anderson J, Bennett C, Goldman JM, Guilhot F, Kantarjian HM, Lichtin AE, Talpaz M, Tura S.

Blood. 1999 Sep 1;94(5):1517-36. Review.

8.

Chronic myeloid leukemia: standard treatment options.

Frame D.

Am J Health Syst Pharm. 2006 Dec 1;63(23 Suppl 8):S10-4; quiz S21-2. Review.

PMID:
17106015
9.

Early allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era: a preliminary assessment.

Simon W, Segel GB, Lichtman MA.

Blood Cells Mol Dis. 2006 Sep-Oct;37(2):116-24; discussion 125-7. Epub 2006 Aug 10.

PMID:
16904348
10.

Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia.

Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber SL, Beck JR.

Ann Intern Med. 1996 Oct 1;125(7):541-8.

PMID:
8815752
11.

Cytarabine added to interferon improves the cost-effectiveness of initial therapy for patients with early chronic phase chronic myelogenous leukemia.

Beck JR, Guilhot J, Giles FJ, Aoki N, Wirt DP, Guilhot F.

Leuk Lymphoma. 2001 Mar;41(1-2):117-24.

PMID:
11342363
12.

Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.

Warren E, Ward S, Gordois A, Scuffham P.

Clin Ther. 2004 Nov;26(11):1924-33.

PMID:
15639704
13.
14.

T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.

Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA.

Blood. 1999 Jul 15;94(2):434-41. Erratum in: Blood 2000 Feb 15;95(4):1137.

15.

Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.

Wong SF, Mirshahidi H.

Ann Pharmacother. 2011 Jun;45(6):787-97. doi: 10.1345/aph.1P784. Epub 2011 Jun 13. Review.

PMID:
21672900
16.

[Recommendations for diagnosis, treatment and monitoring of chronic myeloid leukemia].

Almeida A, Castro I, Coutinho J, Guerra L, Marques H, Pereira AM.

Acta Med Port. 2009 Sep-Oct;22(5):537-44. Epub 2009 Oct 22. Portuguese.

17.

Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.

Williams C, Brunskill S, Altman D, Briggs A, Campbell H, Clarke M, Glanville J, Gray A, Harris A, Johnston K, Lodge M.

Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. Review.

18.

[Therapy of chronic myelogenous leukemia in 2004].

Hochhaus A, Berger U, Hehlmann R.

Dtsch Med Wochenschr. 2004 Oct 1;129(40):2122-7. Review. German.

PMID:
15455305
19.

Successful treatment of lymphoid blastic crisis in chronic myelogenous leukemia with the additional bcr/abl transcript using imatinib-combined chemotherapy and high-dose chemotherapy with allogeneic bone marrow stem cell transplantation.

Kawano N, Okuda S, Yoshida S, Kugimiya H, Ito M, Horikawa N, Chosa N, Hisakata T, Fukudome T, Sakurai R, Yamashita K, Ueda A, Kanda Y.

Int J Hematol. 2011 Dec;94(6):561-6. doi: 10.1007/s12185-011-0956-y. Epub 2011 Nov 8.

PMID:
22057509
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk